glp 1 drugs and mental health An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive disorders Now, new research suggests that

105 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Overgaard RV, Petri KC, Jacobsen LV, Jensen CB

(Try discount sites such as TrumpRx or GoodRx.) Even with discounts, the drugs are not affordable for everyone

Many of the neuroprotective, neurodegenerative, psychiatric, and addiction-related applications discussed remain investigational, and no GLP-1 receptor agonist is currently approved by regulatory authorities for the treatment or prevention of Alzheimers disease, Parkinsons disease, depression, substance use disorders, or other neurological indications unless specifically stated otherwise

Individuals who used GLP-1RAs for 0.5, 1, and 1.5 years had IRRs close to 1.0, with no significant decrease in MACE risk at three years, although these estimates varied across specific treatment strategies defined by prior duration and subsequent exposure patterns

10.1038/ijo.2014.153 78 QiQ.ZhangH.JinZ.WangC.XiaM.ChenB.et al (2024)